Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Regeneron Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $5,791 Mil.
Regeneron Pharmaceuticals's annual Marketable Securities
declined
from Dec. 2023 ($8,115 Mil) to Dec. 2024 ($6,524 Mil) and
declined
from Dec. 2024 ($6,524 Mil) to Dec. 2025 ($5,487 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Regeneron Pharmaceuticals Marketable Securities Related Terms
Regeneron Pharmaceuticals Marketable Securities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of $5,791 Mil mean?
Regeneron Pharmaceuticals (LTS:0R2M) has a Marketable Securities of $5,791 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Marketable Securities too high?
Regeneron Pharmaceuticals' current Marketable Securities is $5,791 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Marketable Securities compare to RVMD and ALNY?
Regeneron Pharmaceuticals' Marketable Securities of $5,791 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Marketable Securities is $5,791 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $902.72, compared to a current price of $662.48 — trading 26.6% below its estimated fair value. The current Marketable Securities is $5,791 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Marketable Securities is $5,791 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $662.48 is trading 26.6% below its estimated GF Value™ of $902.72.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for LTS:0R2M:
Marketable Securities: $5,791 Mil
GF Value™: $902.72 vs. price of $662.48 (26.6% below fair value)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score
Get the complete analysis for LTS:0R2M
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
